1. Market Research
  2. > Healthcare Market Trends
  3. > Healthcare Analysis & Statistics, January 2014 (p8)

Healthcare Analysis & Statistics, January 2014 (p8)

211-211 of about 200 reports

Physician Views: How do Indian oncologists plan to use biosimilar Herceptin?

Physician Views: How do Indian oncologists plan to use biosimilar Herceptin?

  • $ 781
  • Industry report
  • January 2014

Biocon's CANMAb – a biosimilar version of Roche's HER2-positive breast cancer treatment Herceptin (trastuzumab) – is to launch on the Indian market in the first week of February.Kiran Mazumdar-Shaw ...

  • Industries : Cancer, Medical Biotechnology, Pathology
  • Countries : India

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on